Jump to content

Are you chasing returns in the US markets?


Recommended Posts

The last ten years have seen US equities outperform European equities. In GBP terms the S&P 500 gained 225% in the decade to the end of July 2017, while the MSCI Europe Index lagged significantly behind with a gain of 74%.

 

The majority of the US out-performance was generated after the 2008-2009 financial crisis, during a period where European equities were facing sovereign debt problems in the eurozone periphery and deflation loomed until the ECB began their program of quantitative easing.

 

US stocks now trade on a price-to-book ratio of 3.1 times. With MSCI Europe at 1.8 times this represents a relative 72% valuation premium for US stocks. While US has always traded at a premium to Europe, right now it is approaching the most expensive it has ever been based on this valuation measure.

 

As an investor, which valuation measures would you look at to say whether US equities are currently expensive or not? 

 

Have a question for me? 'Ask an expert' using the comments section below and I'll make sure to reply. This synopsis is part of a wider article here

 

2017-10-25 13_22_12-Are you chasing returns in the US markets_ _ IG UK.png

 

Link to comment

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • General Statistics

    • Total Topics
      15,674
    • Total Posts
      74,994
    • Total Members
      63,042
    • Most Online
      7,522
      10/06/21 10:53

    Newest Member
    SelfIsolating2021
    Joined 27/07/21 09:14
  • Posts

    • Gold falls back into support as Brent crude pushes into Fibonacci resistance Gold falls back into key support, while Brent crude has rallied up into Fibonacci resistance in its bid to regain previous highs. Source: Bloomberg    Joshua Mahony | Senior Market Analyst, London | Publication date: Tuesday 27 July 2021  Gold drifts back into key support level Gold has been on the back foot once again, with price moving back into the key $1790 support level. A break below that level would bring a bearish picture into play following a period of consolidation. However, with price typically managing to post a short rebound from this level, it is worthwhile expecting another move higher until we see $1790 break. Source: ProRealTime   Brent crude rallies back into Fibonacci resistance Brent crude has been on the rise since a pullback into the wider 76.4% Fibonacci retracement level at $67.60. That rally has brought us back into yet another 76.4% level at $74.12. The wider uptrend points towards a likely push up through this level in a bid to regain the previous peaks of $76.30 and $77.57. However, whether that will come in a straight line remains to be seen. For now, we need to see whether price respects that Fibonacci resistance level or simply pushes through. To the downside, any pullback would need to break the $72.14 level to bring a more bearish short-term outlook. Until then, there is a good chance we see further upside come into play. Source: ProRealTime   See opportunity on a commodity?  
    • Astrazeneca Q2 revenue is expected to show strong growth, although an increased cost base will pressure underlying earnings. Source: Bloomberg   Shares AstraZeneca Price Revenue Earnings before interest, taxes, depreciation and amortization Technical analysis  Shaun Murison | Senior Market Analyst, Johannesburg | Publication date: Tuesday 27 July 2021  When are the AstraZeneca results? AstraZeneca, the biopharmaceutical company, earnings release date is scheduled for 27 July 2021. The scheduled results will cover the groups second quarter (Q2) and half-year earnings. What to expect from AstraZeneca results? While a large Covid-19 vaccine rollout will have boosted revenue for the group, it would have done little for underlying earnings due to the company selling the product as a non-profit item. Consensus estimates derived from Refinitiv data arrives at the following expectations for Q2 of 2021: Revenue $7.530 billion (+20%) year on year (YoY) Earnings before interest tax depreciation amortisation (EBITDA) $2.233 billion (-10.75% YoY) Earnings per share (EPS) $0.93 (-3.01% YoY) What is expected to be accretive to future earnings for the group (although may weigh in the short term) is the groups acquisition of biopharmaceutical business Alexion, which was concluded on 21 July 2021, shortly after the reporting quarter. Find out more on how to buy, sell and short AstraZeneca shares How to trade AstraZeneca results A Refinitiv poll of 29 analysts maintain a long-term average rating of ‘buy’ for AstraZeneca (as of 26 July 2021), with 10 of these analysts recommending a strong buy, 16 recommending a buy, 1 hold, 1 sell and 1 strong sell recommendation on the stock. Source: IG AstraZeneca share price – technical analysis view Source: IG charts   The share price of AstraZeneca continues to trade in an uptrend which has been in place since the beginning of 2021. The price has however started to correct from near-term highs. Traders respecting the longer-term uptrend will prefer to keep a long bias to trades targeting a retest of the 8770 level, provided that the price does not move to break the confluence of both trend line and horizontal support at the 7800 level. A break of the 7800 level would instead suggest the uptrend to be broken. In summary AstraZeneca results are scheduled for release on 27 July 2021 Q2 revenue of $7.530 billion is expected Q2 EBITDA of $2.223 billion is expected EPS of $0.93 is expected The average broker rating for AstraZeneca is ‘buy’ The share price of AstraZeneca is currently in a short term correction of a longer-term uptrend
×
×
  • Create New...